Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic Wharton's jelly-derived mesenchymal stem cells (FOSCAL)
- Development stage
- Unknown
- Lead developer
- Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Periadventitial
01
Overview
This investigational cell therapy consists of allogeneic mesenchymal stem cells derived from the Wharton's jelly of the umbilical cord (allo-WJ-MSCs). Developed by the Fundación Oftalmológica de Santander (FOSCAL) in Colombia, it is specifically designed for the treatment of chronic limb-threatening ischemia (CLTI) in diabetic patients. The therapy is administered as a single dose injected into the periadventitial layer of the arterial walls under eco-Doppler guidance. The mechanism of action involves the paracrine secretion of pro-angiogenic and immunomodulatory factors by the stem cells, which promotes neovascularization, reduces inflammation, and facilitates tissue repair in severely ischemic limbs. Clinical pilot data demonstrated significant efficacy in limb salvage compared to placebo in patients with advanced Rutherford classification stages.
- Other names
- allogeneic umbilical cord mesenchymal stem cellsallo-WJ-MSCallogeneic Wharton jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic Wharton's jelly-derived mesenchymal stem cells (FOSCAL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic Wharton's jelly-derived mesenchymal stem cells (FOSCAL).